These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26667261)

  • 21. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Hueber W; Tomooka BH; Batliwalla F; Li W; Monach PA; Tibshirani RJ; Van Vollenhoven RF; Lampa J; Saito K; Tanaka Y; Genovese MC; Klareskog L; Gregersen PK; Robinson WH
    Arthritis Res Ther; 2009; 11(3):R76. PubMed ID: 19460157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
    Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of anti-tumor necrosis factor biologics in the treatment of rheumatoid arthritis does not change human T-lymphotropic virus type 1 markers: a case series.
    Umekita K; Umeki K; Miyauchi S; Ueno S; Kubo K; Kusumoto N; Takajo I; Nagatomo Y; Okayama A
    Mod Rheumatol; 2015 Sep; 25(5):794-7. PubMed ID: 24252020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
    Shi R; Chen M; Litifu B
    Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort.
    Smith SL; Plant D; Eyre S; Hyrich K; Morgan AW; Wilson AG; Isaacs JD; Barton A
    Rheumatology (Oxford); 2017 Jun; 56(6):1019-1024. PubMed ID: 28096457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiomics and Machine Learning Accurately Predict Clinical Response to Adalimumab and Etanercept Therapy in Patients With Rheumatoid Arthritis.
    Tao W; Concepcion AN; Vianen M; Marijnissen ACA; Lafeber FPGJ; Radstake TRDJ; Pandit A
    Arthritis Rheumatol; 2021 Feb; 73(2):212-222. PubMed ID: 32909363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
    Smith SL; Alexander S; Nair N; Viatte S; Eyre S; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; Plant D; Barton A
    Ann Rheum Dis; 2023 May; 82(5):611-620. PubMed ID: 36810200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
    Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.
    Raaschou P; Frisell T; Askling J;
    Ann Rheum Dis; 2015 Dec; 74(12):2137-43. PubMed ID: 25107559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
    BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.